A pretreatment ECM-high/immune-low transcriptomic score is associated with pathological complete response after neoadjuvant therapy in breast cancer
PLOS One · 05.11.2026 · 21 (11) · e0357532
DOI: 10.1371/journal.pone.0357532 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS One, online erschienen am 05.11.2026. Verfasst von Tao Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Breast Surgery, Hubei No. 3 People's Hospital of Jianghan University, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Transcriptome, Extracellular Matrix. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In this retrospective public-cohort observational study, we evaluated a biologically motivated extracellular matrix (ECM)-high/immune-low transcriptomic score for association with pathological complete response (pCR) after neoadjuvant therapy in breast cancer. The score contrasted standardized ECM/fibroblast and immune-response components. Cohort-specific logistic models adjusted for available clinical covariates; their performance was evaluated separately and was not validation of a locked transported model. In I-SPY2/GSE194040 (n = 987; 319 pCR events), a one-standard-deviation higher score was associated with lower pCR odds (odds ratio [OR] 0.687, 95% confidence interval [CI] 0.588–0.803). Inverse adjusted estimates were also observed in GSE25066 (OR 0.744, 95% CI 0.568–0.975) and GSE20271 (OR 0.407, 95% CI 0.232–0.715). Apparent areas under the receiver operating characteristic curve (AUCs) for these multivariable models were 0.750, 0.732 and 0.798; corresponding 500-bootstrap optimism-corrected estimates were 0.731, 0.713 and 0.765, conditional on processed scores. GSE20194 estimates were nonsignificant, and substantial record overlap with GSE25066 prevented interpretation as additional independent confirmation. A GSE25066 sensitivity restricted to deposited human epidermal growth factor receptor 2 (HER2)-negative status retained direction but had a confidence interval crossing unity. Higher scores correlated with lower immune-related reverse-phase protein array signals in matched I-SPY2 samples. The findings support a hypothesis-generating bulk-transcriptomic response association, with limited cross-cohort robustness. Heterogeneous treatment, sampling, assay and endpoint annotations, together with absent spatial and prospective validation, preclude claims of causality or clinical treatment-selection utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Thyroid and Breast Surgery, Hubei No. 3 People's Hospital of Jianghan University, Wuhan, Hubei, China.
- Department of Cardiothoracic, Thyroid and Breast Surgery, Enshi Central Hospital, Enshi, Hubei, China.
ORCID-Profile: Tao Wang
Zitieren
APA
Wang, T., & Wu, X. (2026). A pretreatment ECM-high/immune-low transcriptomic score is associated with pathological complete response after neoadjuvant therapy in breast cancer. PLOS One, 21(11), e0357532. https://doi.org/10.1371/journal.pone.0357532
Vancouver
Wang T, Wu X. A pretreatment ECM-high/immune-low transcriptomic score is associated with pathological complete response after neoadjuvant therapy in breast cancer. PLOS One. 2026;21(11):e0357532. doi:10.1371/journal.pone.0357532
BibTeX
@article{Wang2026,
author = {Wang, Tao and Wu, Xiaoyun},
title = {A pretreatment ECM-high/immune-low transcriptomic score is associated with pathological complete response after neoadjuvant therapy in breast cancer},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {11},
pages = {e0357532},
doi = {10.1371/journal.pone.0357532}
}
EUVIMED